CiteFacts · FDA Drug Shortages · FDA source
Lisdexamfetamine Dimesylate Tablet, Chewable
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Novadoz Pharmaceuticals LLC | Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91) | Available | 08/17/2026 |
| Novadoz Pharmaceuticals LLC | Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91) | Available | 08/17/2026 |
| Novadoz Pharmaceuticals LLC | Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91) | Available | 08/17/2026 |
| Novadoz Pharmaceuticals LLC | Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91) | Available | 08/17/2026 |
| Novadoz Pharmaceuticals LLC | Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91) | Available | 08/17/2026 |
| Novadoz Pharmaceuticals LLC | Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91) | Available | 08/17/2026 |
| Sun Pharmaceutical Industries, Inc. | Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88) | Available | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88) | Available | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88) | Available | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88) | Available | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88) | Available | 08/05/2026 |
| Sun Pharmaceutical Industries, Inc. | Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88) | Available | 08/05/2026 |
| Takeda Pharmaceuticals USA Inc. | Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01) | Available | 06/23/2026 |
| Takeda Pharmaceuticals USA Inc. | Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01) | Available | 06/23/2026 |
| Takeda Pharmaceuticals USA Inc. | Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01) | Available | 06/23/2026 |
| Takeda Pharmaceuticals USA Inc. | Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01) | Available | 06/23/2026 |
| Takeda Pharmaceuticals USA Inc. | Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01) | Available | 06/23/2026 |
| Takeda Pharmaceuticals USA Inc. | Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01) | Available | 06/23/2026 |
Source facts
Grouped generic ingredient: Lisdexamfetamine Dimesylate Tablet, Chewable · 18 package records · Latest FDA row update: 08/17/2026
Therapeutic categories: Psychiatry
Dosage forms: Tablet, Chewable
Routes: ORAL
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.